Hereditary neuropathies comprise a wide variety of chronic diseases associated to more than 80 genes identified to date. We herein examined 612 index patients with either a CharcotMarie-Tooth phenotype, hereditary sensory neuropathy, familial amyloid neuropathy, or small fiber neuropathy using a customized multigene panel based on the next generation sequencing technique. In 121 cases (19.8%), we identified at least one putative pathogenic mutation. Of these, 54.4% showed an autosomal dominant, 33.9% an autosomal recessive, and 11.6% an X-linked inheritance. The most frequently affected genes were PMP22 (16.4%), GJB1 (10.7%), MPZ, and SH3TC2 (both 9.9%), and MFN2 (8.3%). We further detected likely or known pathogenic variants in HINT1, HSPB1, NEFL, PRX, IGHMBP2, NDRG1, TTR, EGR2, FIG4, GDAP1, LMNA, LRSAM1, POLG, TRPV4, AARS, BIC2, DHTKD1, FGD4, HK1, INF2, KIF5A, PDK3, REEP1, SBF1, SBF2, SCN9A, and SPTLC2 with a declining frequency.
Hereditary neuropathies comprise a wide variety of progressively disabling diseases; amongst them prevail those, which are not treatable to date. A clear diagnostic distinction is based on both a phenotypic characterization and a molecular genetic verification. Especially, if an identified variant is yet undescribed in the literature, next generation sequencing (NGS) based molecular genetic analyses are of utmost importance to substantiate a diagnosis and to understand the geno-and phenotypic disease spectrum as well as the underlying pathomechanisms.
With an approximate worldwide prevalence of 1 in 2500 individuals (Wiszniewski et al. 2013) , Charcot-Marie-Tooth disease (CMT; alternative designation: hereditary motor and sensory neuropathy), despite being considered a rare disease, forms the broadest subgroup of hereditary neuropathies distinguished by their clinical and paraclinical patterns (for review see Pareyson and Marchesi 2009; Rossor et al. 2013) . The typical phenotype encompasses distal symmetric muscle weakness and atrophy, foot deformities such as pes cavus, comparably milder sensory loss, and reduced or absent tendon reflexes. Corresponding to electrophysiological studies and mode of inheritance, a subclassification into the types CMT 1-4 has been traditionally applied (Dyck et al. 1963; Dyck and Lambert 1968) . Frequently involved genes are PMP22, GJB1, MPZ and MFN2 (DiVincenzo et al. 2014 ).
However, approximately 80 different genes are known to date to be disease causing in the context of CMT when mutated. Neuropathies with a pure motor involvement are classified as distal hereditary motor neuropathies, for example, caused by mutations in HSPB1 or HSPB8 (Rossor et al. 2012) . Leading sensory loss, neuropathic pain, ulceromutilation and/or autonomous symptoms such as incontinence, impotence, disturbed sweating, or dysregulation of blood pressure are defined as hereditary sensory and autonomous neuropathies (HSAN) (Rotthier et al. 2012) . As an example of pathophysiological importance in this study, gainof-function missense mutations in SPTLC1 or SPTLC2 lead to an increased amount of the two neurotoxic1-deoxy-sphingolipid bases 1-deoxy-sphinganine and 1-deoxy-sphingosine in HSAN1A and C (Gable et al. 2010; Penno et al. 2010) . Small fiber neuropathies imply a chronic pain syndrome under electrophysiological exclusion of large fiber involvement. However, disease mechanisms are not fully understood, and underlying (hereditary) causes, such as mutations in SCN9A, are only identified in a small number of affected cases (Faber et al. 2012) . Of special therapeutic relevance is the systemic transthyretin (TTR)-related amyloidosis, which initially manifests with a mixed sensorimotor and autonomous neuropathy and later results in a progressive lethal course through cardiac involvement and multiorgan failure (Andrade 1952) if untreated. Causative treatment options such as liver transplantation (Holmgren et al. 1993) removing the main source of mutated TTR or TTR-stabilizing small molecules (Coelho et al. 2012) are only approved for the first disease stage, which makes early genetic counseling essential.
In all types of hereditary neuropathies, an accurate diagnosis is made by the molecular genetic identification of the underlying pathogenic variant(s). Notwithstanding, geno-and phenotypes are not unambiguously assignable, and the variety of known genes involved in the pathogenesis renders the diagnostic counseling by stepwise Sanger sequencing virtually impossible (Rossor et al. 2013) . Multiple simultaneous next generation sequencing facilitates not only the decoding of entire exomes or genomes, in which the gene coverage has been a methodical limitation, but also of diagnose-specific panels guaranteeing a sufficient coverage of all relevant genes included in the respective gene compilation (Rehm 2013) .
In this study, we depict and retrospectively discuss our results on panel-based molecular genetic examinations of 612 patients with the suspected diagnosis of a hereditary neuropathy. For being considered as likely disease causative (Richards et al. 2015) , a DNA alteration must have either led to a shift of the transcript reading frame, caused a nonsense mutation inducing a premature stop codon, changed the canonical splice-site sequence, resulted in an alteration of the deduced amino acid sequence, which is predicted to be damaging, or been previously reported as to be pathogenic in the literature. A particular aim of this study was to discuss more than 30 novel variants in terms of putative pathogenicity and highlight the advantages of the multiple gene panel approach in the clinical context.
Materials and methods
Six hundred and twelve genomic DNAs were analyzed by next generation sequencing applying the multiple gene panel approach, which provides simultaneous analysis of all known genes associated to hereditary neuropathies. Enrichment kit and the method used were established, validated, and provided by the CeGaT GmbH, T€ ubingen, Germany. CeGaT is accredited by DAkkS according to DIN EN ISO 15189:2014 . Accreditation is effective for the scope of activities as defined in the certification annex [D-ML-13206-01-00].
Patients
The underlying blood specimens were obtained at different clinical centers, most of which located in Germany. In all cases, the suspected diagnosis made by the requesting clinicians was 'hereditary neuropathy'. Additional information such as clinical phenotype, electrophysiology, family history, or premedication were not provided by all senders.
Prior to analysis, the patients' consent for genetic testing was obtained on the requesting form. In addition, on that same form, we enclosed an option to mark whether patients agreed with a scientific data use. In a cohort of 121 genetically solved cases, 15 patients did not explicitly agree nor disagree by neither crossing the 'yes' nor the 'no' option. Two patients explicitly indicated their disagreement. To avoid a remarkable bias in the distribution of affected genes with a considerable impact on the results of this article, we will therefore name the involved genes for statistical reasons, but not disclose any specific information on the particular variants. For this purpose, we anonymously extracted the overall distribution of affected genes out of the local in-house database. In accordance with the German Data Protection Act, a retrospective and utterly anonymous evaluation of patient data does not require a particular consent. We were thereby able to reduce a significant selection bias without injuring the rights of our participating patients. Both the molecular genetic analysis and the retrospective depiction of all identified variants were performed according to the local and legal guidelines (Richards et al. 2015; Matthijs et al. 2016) and to the declaration of Helsinki. The study has been approved by the ethical committee of the medical faculty of the RWTH Aachen university (EK127-17). Because of its retrospective character, no pre-registration was filed for this study.
DNA extraction
From patients' blood samples, genomic DNA was isolated according to the manufacturers' recommendations either using QIAamp DNA Blood Maxi Kit or QiaSymphony (Qiagen, Hilden, Germany). DNA quantity and quality were determined using both the Qubit â Fluorometer and NanoDrop ND-8000 (Thermo Fisher Scientific, Dreieich, Germany).
Multiplex ligation probe amplification
Deletion/duplication testing of the PMP22 gene was performed by multiplex ligation probe amplification (MLPA) analysis using (MRC Holland, SALSA MLPA CMT1 Kit P033-B4-V25), when stepwise analysis was requested, which understood proceeding with sequencing of entire gene-panel in case of negative results of MLPA analysis. The evaluation was performed based on relative quantification in comparison to reference sample DNA according to the manufacturers' instructions.
NGS laboratory
Since patients were genetically analyzed between the years 2013 and 2016, gene panel sets changed over time. For all patients, 54-84 genes were analyzed (Table 1) . The coding regions and flanking intronic regions were enriched using Agilent in-solution technology. We used a customized target-in-solution-enrichment for exonic regions as well as exon-intron boundaries. Deep intronic variants were included in the enrichment if listed as pathogenic in the human gene mutation database. For sequencing we used either the SOLiD 5500xl System (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA USA/Life Technologies, Grand Island, NY, USA) or the Illumina HiSeq2500 and HiSeq4000 systems (Illumina, San Diego, CA 92122 USA).
Computational analysis
The 75 base pair reads produced by the SOLiD 5500xl platform were analyzed using Lifescope software version 2.1 or 2.5 (Life Technologies). Reads were mapped to the human reference genome (hg19) with a blast-like mapping algorithm using color codes. The calling of single nucleotide variants and small insertions/deletions (indels) was implemented with a Frequentist algorithm on high coverage positions or a Bayesian algorithm.
Sequencing reads generated by the Illumina platforms were demultiplexed using Illumina CASAVA (1.8.2) (Illumina, San Diego, CA 92122 USA). Adapter sequences were removed with Skewer 0.1.116 and the trimmed reads mapped to the human reference genome (hg19) using the Burrows Wheeler Aligner (BWA-mem 0.7.2) (Li and Durbin 2010) . Reads mapping to more than one location with identical mapping scores were discarded (internal software). Read duplicates likely resulting from PCR amplification were removed (samtools 0.1.18). Variants were called using samtools and varscan (2.3.3) (http://dkoboldt.github. io/varscan). Technical artifacts were removed (in-house software) 
The gene numbers refer to the gene transcript used in this study. We additionally list the particular panel version, which was comprised by the defined gene set. and the remaining variants were annotated based on several internal and external databases.
Calling of copy number variations
Copy number variations were computed using an internally developed method based on sequencing coverage depth. Briefly, we used at least 10 reference samples to create a model of the expected coverage that represents biases introduced by the target enrichment method, sequence GC content, library preparation protocol, insert size and sequencing technology, as well as inter-sample variation. Copy number variations calling for germline samples was performed by computing the sample's coverage profile, correcting for total read count and computing the deviation from the expected coverage. Genomic regions are called as variant if they deviate by at least two standard deviations from the model mean and the deviation is concordant with a biologically possible copy number (e.g., +50% for a heterozygous duplication, À50% for a heterozygous deletion), as well as with variant calls (i.e., heterozygous variant calls contradict a heterozygous deletion at the same locus).
Diagnostic data analysis
Only variants (single nucleotide variants/Small Indels) in the coding region and the flanking intronic regions (AE 8 bp) with a minor allele frequency (MAF) < 1.5% were evaluated. Known disease-causing variants (according to human gene mutation database) within AE 30 bp of flanking regions and up to 5% MAF were also evaluated. Minor allele frequencies were taken from the following databases: 1000 Genomes, dbSNP, Exome Variant Server, ExAC, and an in-house database.
At least one causative or rare variant was resequenced using conventional Sanger sequencing, providing a second, independent, confirmation. Individual medical reports for all patients contained all variants with a MAF < 1% (in genes with autosomal recessive modes of inheritance) or < 0.1% (in genes with autosomal dominant modes of inheritance), not including variants classified as benign according to the current literature. In silico prediction of variants was calculated based on the output of the programs Mutation Taster, fathmm, Mutation Assessor, SIFT, fathmm-MKL coding, LRT, and PROVEAN. To assess the consequences of variants on splicing, two algorithms were applied (Jian et al. 2014) which were complemented with additional in silico predictions (NetGene, Fruitfly) in individual cases.
Mutation definition
In general, every permanent DNA alteration is defined as a mutation. In this study, the term mutation refers to all identified DNA variants we consider to be pathogenic and explaining the patient's phenotype. Detected variants were evaluated according to the recommendations of the American College of Genetics and Genomics and subdivided into three main groups: known pathogenic, which have previously been described in the literature, likely pathogenic, which have not been previously reported, but given the consequence (premature stop codon, essential splice, and frame shift) are considered to be pathogenic, and variants of uncertain clinical significance -in most cases previously unreported missense variants, which could potentially be pathogenic (Richards et al. 2015) . All previously undescribed variants were further evaluated in the sense of clinical phenotype, familial anamnesis and, if available, co-segregation analysis. Variants are named as suggested by http:// www.hgvs.org (Den Dunnen and Antonarakis 2000). Novel mutations are listed in Table 2 in alphabetical order of gene names.
Analysis of sphingoid bases
One patient's (Patient 56, Table S1 ) sphingolipid plasma profile was analyzed at the Institute for Clinical Chemistry of the University Hospital Z€ urich, Zurich, Switzerland, as has been described earlier (Penno et al. 2010) . Results were compared to a healthy control person from the institute's reference database and to the literature. The following sphingoid bases were examined: C 16 SO, C 16 SA, C 17 SO, C 17 SA, C 18 SO, C 18 SA, C 19 SO, C 20 SO, C 20 SA, sphingadiene, and the two 1-deoxySL variants deoxy-sphingosine and deoxy-sphinganine.
Long chain bases (LCB) are typically N-acylated and conjugated to different headgroups, which forms a great variety of sphingolipid subspecies. We therefore performed an acid/base hydrolysis to analyze the LCB profile as a measure of serine palmitoyl-coA transferase activity and its product spectrum. Briefly, 0.5 mL methanol including 200 pmol of the internal standards d7-sphingosine and d7-sphinganine (d7SA, d7SO; Avanti Polar Lipids, Alabaster, Alabama, USA) were added to 100 lL of heparin plasma and extracted for 1 h under agitation on a thermo-mixer at 37°C. Precipitated proteins were pelleted by centrifugation and the supernatant transferred to a new tube. For lipid hydrolysis, 75 lL of methanolic HCl (1 N HCl and 10 M H2O in methanol) was added to the supernatant and incubated for 16 h at 65°C. The reaction was stopped by the addition of 100 lL of 10 M KOH. Finally, 625 lL chloroform, 100 lL ammonium hydroxide (2N), and 0.5 mL alkaline water were added in this order. The mix was vortexed and centrifuged at 16 000 g for 5 min to separate the phases. After centrifugation, the upper phase was discarded and the lower organic phase was washed two to three times with alkaline water (pH 10.3). Finally, the organic phase was dried under N2 and kept at À20°C freezer until analysis. To have an orthogonal identification criterion as well as to increase ionization and sensitivity of the analysis, the LCBs were derivatized with ophthalaldehyde (OPA) prior to analysis. For analysis, lipids were dissolved in 75 lL Derivatization mix (56.7% MeOH, 33.3% EtOH, 10% H2O) and derivatized with 5 lL of OPA working solution (990 lL boric acid [3%] + 10 lL OPA [50 mg/mL in EtOH] + 0.5 lL 2-Mercaptoethanol). The LCBs were separated for 30 min on a reverse phase C18 column (Uptispere 120 A, 5 lm, 125 9 2 mm, Interchim, Mannheim, France) with an isocratic mobile phase (1 : 1 methanol/ammonium acetate (5 mM; Sigma, St Louis, MO, USA) in water) at a flowrate of 400 lL/min. After each run, the column was regenerated for 10 min with 100% MeOH. Spectra were recorded on a triple quad MassSpec (TSQ Quantum Ultra; Thermo). Intra-and inter-assay variation coefficient was between 5% and 20% (Othman et al. 2015) .
Statistical analysis
In this work, we re-evaluated all NGS-based molecular genetic cases processed by the CeGaT GmbH being requested with the suspected diagnosis 'hereditary neuropathy' between 02/2013 and 08/2016 (n = 612). Because of the retrospective character of this study, we were not able to perform any preliminary sample size calculation or power analysis. As phenotypical information was essentially required for the evaluation of molecular genetic data, there was no blinding performed. The distribution of mutated genes identified in this study was calculated following basic statistical procedures via Excel. The plasma sphingolipid profile was analyzed and compared to a healthy control proband as well as to the literature as described and cited in the respective section. Because of the low sample size, we were not able to perform any column statistics to examine an underlying normal distribution or to calculate the level of significance by application of t-tests.
Results
Molecular genetic spectrum Specimens of 612 index patients with the suspected diagnosis of an inherited neuropathy were examined between February 2013 and August 2016. In 290 cases (47.4%), no explanatory molecular genetic cause was identified. Another 201 cases (32.8%) were classified as being uncertain, since the detected variants of uncertain clinical significance could not have been conclusively evaluated concerning their pathogenicity. In 121 cases (19.8%), a previously described or likely pathogenic variant was found (Table S1 ). Novel likely pathogenic variants accounted for 30% of these. In this study, we excluded 17 of these genetically solved cases, seven of which caused by novel variants, because of lack of consent. To maintain the overview of the involved genes and their distribution, we will mention the gene names and number of affected cases (Table 3 ; Fig. 1 ), but exclude the patients from the detailed description of molecular genetic and/or clinical data (Table 2; Tables S1 and S3 ). The most frequently identified genes in our cohort of 121 patients with putative pathogenic variants were PMP22 (16.4%), GJB1 (10.7%), MPZ and SH3TC2 (both 9.9%), and MFN2 (8.3%). PMP22 was the most relevant gene predominantly showing copy number variations: The PMP22 duplication accounted for 9.9% of all variants, whereas the incidence of deletion rose up to 2.9%. Despite its X-linked (XL) inheritance, 40% of the patients with a likely pathogenic variant in GJB1 were female. Variants in MFN2 followed an autosomal dominant (AD) mode of inheritance in eight of ten cases comprising 6.6% of all positive cases, and an autosomal recessive (AR) in one case forming 1.7%. Other putative pathogenic variants were found in the following genes (with a declining frequency): HINT1 (n = 5), HSPB1, NEFL, PRX (n = 4 each), IGHMBP2, NDRG1, TTR (n = 3 each), EGR2, FIG 4, GDAP1, LMNA, LRSAM1, POLG, TRPV4 (n = 2), AARS, BIC2, DHTKD1, FGD4, HK1, INF2, KIF5A, PDK3, REEP1, SBF1, SBF2, SCN9A, and SPTLC2 (n = 1 each; Table S1 ).
In our cohort, 54.5% of the positive cases showed an AD inheritance, whereas it was AR in 33.9%, and XL in 11.6%.
As detailed information on the cases and variants are required below, we will hereinafter confine our description on the 104 individuals only, of whom the consent for scientific data use is confirmed: Of the recessively inherited cases, 43.7% were caused by a homozygous variant, and 56.3% by two compound heterozygous mutations. One case was identified carrying two homozygous likely pathogenic variants in the POLG gene (patient 81, Table S1), and AD, autosomal dominant; AR autosomal recessive; CMT, Charcot-Marie-Tooth disease; MLPA, multiplex ligation probe amplification; XL, X-linked; het., heterozygous; homo., homozygous; comp. het., compound heterozygous; hemi., hemizygous. *Co-segregation analyses performed (Table S3 ); **classification of pathogenicity based on the criteria by Richards et al. 2015 ; pvs, very strong evidence of pathogenicity; ps, strong evidence of pathogenicity; pm, moderate evidence of pathogenicity; pp, supporting evidence of pathogenicity. For being 'likely pathogenic', the following criteria need to be fulfilled: 1 pvs and 1 pm or 1 ps and 1-2 pm or 1 ps and 2 pp or 3 pm or 2 pm and 2 pp or 1 pm and 4 pp. Description of all mutations identified in our cohort, which have not been previously described. The mutations are listed following alphabetical order of the affected gene. To interpret the pathogenicity of each variant, we herein explain the underlying mechanisms. In cases of compoundheterozygosity, the second mutation will only be depicted if novel as well. The fulfilled criteria (Richards et al. 2015) for each variant being 'likely pathogenic' are listed on the right. For a detailed summary of all variants, we refer to our supplementary material (Table S1 ).
another patient even showed three homozygous variants (patient 72, Table S1 ): two in HK1, and another homozygous potentially pathogenic one in EGR2. We will report on patient 72 in detail in a subsequent part of this manuscript. The included patients were male in 48.1% and female in 51.9%. The family history contained other known affected relatives in 35.5% (45% of all AD cases, 18.8% in the AR subcohort, 25.3% in case of XL inheritance) and was negative in 47.2% (AD: 37.7%, AR: 62.5%, XL: 45.5%). In another 17.3% (AD: 14.8%, AR: 18.6%, XL: 27.3%), information on familial anamnesis was not available. One patient of the AD group (patient 14, Table S1 ) was adopted. Co-segregation analyses were performed in 16.4% of the AD cases, and in 31.3% of the AR ones (Table S3) .
Novel variants
In this study, we describe 34 putative pathogenic variants, which have not been described in the literature so far (Table 2) . Eight of these were detected in the following AD genes: AARS (n = 1), HSPB1 (n = 1), INF2 (n = 1), KIF5A (n = 1), MFN2 (n = 1), MPZ (n = 2), and SPTLC2 (n = 1). With an AR inheritance, we identified 22 novel variants in FGD4 (n = 2), FIG 4 (n = 1), GDAP1 (n = 1), IGHMPB2 (n = 3), MFN2 (n = 1), NDRG1 (n = 1), PRX (n = 6), SBF1 (n = 2), and SH3TC2 (n = 5). In the following two XL genes, we detected further four novel variants: GJB1 (n = 3), and PDK3 (n = 1). The underlying pathogenicity was substantiated by the type of mutation, mode of inheritance, allele frequency, and matching phenotype. Of the 34 novel variants, nine were frameshift mutations (26.5%), four nonsense mutations leading to a premature stop codon (11.8%), four splice-site mutations (11.8%), three copy number variations (8.8%), and 14 missense mutations in a relevant protein domain, affecting a highly conserved amino acid and/or being predicted to be damaging by in silico testing (41.1%). Following the criteria of Richards and colleagues (Richards et al. 2015) , all novel variants described in this work were classified as being 'likely pathogenic' (the respective criteria applied for each variant are listed in Table 2 ).
Case descriptions
In the following, we will briefly describe four cases discussing some special aspects when interpreting the molecular genetic dataset, respectively. AD, autosomal dominant; AR autosomal recessive; TTR, transthyretin; XL, X-linked; n, number of cases. Defined by the respective mode of inheritance, this table depicts the overall amount and percentages of mutations identified in the examined genes.
The given values were rounded to one decimal figure.
HK1: two homozygous variants detected by the gene panel analysis
In patient 72, we identified two homozygous variants in HK1 encoding for the ubiquitous protein hexokinase 1, which catalyses the essential phosphorylation of glucose to glucose-6-phosphate at the beginning of glycolysis. The first homozygous variant g.9712G>C (c.-249-3818G>C, rs397514654) is located in a highly conserved, untranslated exonic region and has been first described as a founder mutation in the hereditary motor and sensory neuropathy Russe type (CMT4G) in a Spanish gypsy population (Hantke et al. 2009; Sevilla et al. 2013) . The second, likewise homozygous variant g.11027G>A (c.-249-2503G>A, rs545102911) is located in the adjacent intron and has also been described by the aforementioned authors. However, the pathogenicity remains unclear. It is remarkable that both variants in HK1 were detected in a position outside of the translated exon sequence. In case of whole exome sequencing, the detection of both variants would thus have failed (Fig. 2) , characterizing a distinct advantage of targeted panel diagnostics in this case. As the haplotypes of HK1 and EGR2 are closely related on chromosome 10q23, we additionally reported the variant c.1352G>T; p.Gly451Val of uncertain significance in EGR2, which has been previously described as a likely benign polymorphism (Takashima et al. 2001; Koutsis et al. 2013) . However, in these publications, the described variant was in a heterozygous state while being homozygous in our patient. In silico prediction programs predicted inconsistent pathogenicity. We are therefore not able to exclude that the identified variant in EGR2 contributes to the patient's phenotype.
KIF5A: phenotypic overlap between CMT and HSP
The 48-year-old male patient (Patient 9, Table S1 ) noticed first signs of gait unsteadiness at the age of 44. He soon developed severe steppage gait and provided distinct symmetric calf atrophy, pedes cavi and claw toes when first presenting. Surprisingly, the deep tendon reflexes where vivid except for the absent ankle jerk reflex, which was unexpected considering the amount of atrophy at that stage of presumed CMT. There were mild to moderate signs of sensory loss. Nerve conduction studies of the legs showed an axonal motor neuropathy, while being normal in the arms. The molecular genetic analysis detected the heterozygous variant c.785T>C; p.Leu262Pro in the KIF5A gene.
Following an autosomal dominant mode of inheritance, pathogenic mutations in KIF5A are known to cause a hereditary spastic paraparesis/paraplegia of type 10 (SPG10) or an axonal CMT subtype (Crimella et al. 2012) . A mixed phenotype of these two diseases has previously been described including the typical clinical CMT patterns, Fig. 1 Distribution of likely pathogenic variants in this study. According to Table 3 , the frequencies of all genes harboring at least one likely pathogenic variant are depicted, and concrete percentages are given for every subgroup defined by the autosomal dominant (a, n = 66), autosomal recessive (b, n = 41), or X-linked (c, n = 14) inheritance, respectively.
however, including vivid tendon reflexes or pyramidal signs . The variant c.785T>C; p.Leu262Pro affects a highly conserved amino acid position within a functionally relevant domain. Several other missense mutations are described to be pathogenic in the very close vicinity (Muglia et al. 2014; L opez et al. 2015) . Structural changes on the protein level are conceivable as the linear amino acid leucine is replaced by the cyclic proline at the position 262. Using all available predictions programs, the variant (substitution) is predicted to be pathogenic. No allele frequency is known in the healthy reference population. Unfortunately, no further family members were available to proceed with the co-segregation analysis. Both parents passed away prior to the study.
SPTLC2: increased 1-deoxy-sphingolipid levels in plasma
At the age of 25 years, the now 60-year-old male patient (Patient 56, Table S1 ) developed first signs of sensory loss in both feet including all touch, temperature, and pain perception, and paraesthesias. Because of non-healing wounds and ulcerations, the right thigh was amputated at the age of 36 years. The second thigh amputation was performed when the patient was 55 years old. Hand involvement has been reported since the age of 50. Nerve conduction studies (on both hands) revealed a demyelinating polyneuropathy. The nerve ultrasound showed homogenous nerve enlargements. Over a span of more than 30 years, the underlying cause of neuropathy remained unsolved. As differential diagnosis, a vasculitis or endangiitis obliterans had been discussed. At the age of 28 years, the patient's son has now developed spontaneous limb ulcerations as well.
Molecular genetic testing revealed the novel heterozygous variant c.1148C>T; p.Ala383Val in the SPTLC2 gene. The serine palmitoyl-coA transferase condensates its two substrates forming sphinganine as the first and rate limiting step of sphingolipid synthesis. Gain-of-function mutations (Gable et al. 2010 ) enable the enzyme to metabolize a greater amount of L-alanine and L-glycine (Penno et al. 2010) . Structurally resembling L-serine, the lacking hydroxyl-group in first position, however, impedes both the further metabolization to cerebrosides or gangliosides and the degradation pathways of the resulting 1-deoxy-sphingolipids. Disturbing the axonal outgrowth in a cell culture model (Penno et al. 2010) , the neurotoxicity of accumulated 1-deoxy-sphingolipids has been proven. The heterozygous variant c.1148C>T; p.Ala383Val in SPTLC2 has not previously been described in the literature. At two adjacent positions, however, functionally relevant mutations were reported: heterozygously detected p.Gly382Val and p.Ser384Phe both led to an increase in 1-deoxy-sphingoid bases in the blood plasma (Bode et al. 2015) . We therefore performed a biochemical analysis of the patient's sphingolipid profile in plasma showing a markedly increased amount of two neurotoxic sphingoid bases 1-deoxy-sphingosine and 1-deoxy-sphinganine (Fig. 3) as proof of substantial gain of function. Although C18-sphingosine (70.48 lmol/L) and C18-sphinganine (2.33 lmol/L), the regular and most abundant sphingoid bases, did not show any distinct differences from a normal control individual and from reference values throughout the literature (Gable et al. 2010; Penno et al. 2010 ), 1-deoxy-sphingosine was fourfold (0.42 lmol/L) and 1-deoxysphinganine tenfold increased (0.18 lmol/L) from normal. 
MPZ: second chance for a pathogenic variant
The 33-year-old female patient (Patient 29, Table S1 ) first presented with numbness and burning, tingling neuropathic pain in feet, calves, and hands, combined with mild sensory ataxia, stumbling, and beginning impairment of fine motor skills. The clinical examination further revealed slight pedes cavi and mild pareses of the intrinsic hand muscles. According to the patient's narrative, the symptoms had developed within the past three to four years in a slowly progressive manner. Because of the demyelinating subtype combined with a slight protein elevation (0.56 g/L, reference: < 0.4 g/L) in the cerebrospinal fluid, a chronic inflammatory demyelinating polyneuropathy was alternatively discussed. In a sural nerve biopsy (Fig. 4) , onion bulb formations were depicted (Fig. 4b) ; however, the presence of inflammatory cells was additionally observed (Fig. 4d) . A previous Sanger sequencing had not shown any relevant mutations in PMP22, MPZ, and GJB1.
We then repeated detailed nerve conduction studies showing a distinctly slow motor nerve conduction velocity of the left median (28 m/s, reference: > 48 m/s) and ulnar nerve (23 m/s, reference: > 50 m/s) as well as sensory nerve conduction studies of the left radial nerve (28 m/s, reference: > 55 m/s). F-waves were utterly prolonged (left median nerve: 50.6 ms, reference: < 30.8 ms; left ulnar nerve: 51.8 ms, reference: > 29.8 ms), whereas compound motor action potentials were normal. The subjectively asymptomatic father surprisingly presented with pedes cavi as well, and nerve conduction velocity studies showed comparable results as described for the index patient. We therefore initiated a gene panel analysis targeting hereditary neuropathies, which revealed the known pathogenic variant c.616G>T; p.Gly206* (het.) in MPZ (Senderek et al. 2001) . We confirmed the mutation by additional Sanger sequencing of an independent DNA probe and by co-segregation analysis in the affected father as well. Despite prior alleged exclusion of MPZ mutations, we could thus identify the underlying genetic cause and avoid potentially toxic immunosuppressant treatment.
Discussion
'Frequent genes' -distribution of genes compared to the literature In this study, we reported the genetic spectrum of hereditary neuropathies revealed by the gene panel analysis. Examining up to 84 different genes known to be associated with any type of neuropathy, 121 of 612 cases were solved by identifying at least one likely pathogenic mutation. As depicted in detail in Table 3 , the most frequently detected genes were PMP22, GJB1, MPZ, SH3TC2, and MFN2 (Table 3 , Fig. 1 ) in a declining order.
To integrate our work into the context of the current literature, we chose a representative selection of original articles and reviews submitted by the common web search engines when consulted for the terms 'hereditary neuropathy', 'genetic distribution in hereditary neuropathies', and 'Charcot-Marie-Tooth disease'. The case number varied from n = 438 (Sivera et al. 2013) to n = 17.880 (DiVincenzo et al. 2014) examined patients. Summarized, the previous investigations on the genotypic spectrum of CMT displayed a typical distribution of genes and therefore elaborated recommendation for diagnostic considerations: Throughout the literature, PMP22 duplication accounted for the most frequent mutation in all CMT cohorts (Saporta et al. 2011; Murphy et al. 2012a; Gess et al. 2013; Sivera et al. 2013; DiVincenzo et al. 2014; Fridman et al. 2015; RudnikSch€ oneborn et al. 2016) . DiVincenzo and colleagues showed that within all patients with positive genetic findings, about 95% had mutations in one of the four genes PMP22, GJB1, Fig. 3 Comparison of plasma 1-deoxy-and C18 sphingoid base levels between patient 56 and a healthy control proband. Plasma levels of both 1-deoxy-sphingosine and 1-deoxy-sphinganine (a) were found to be distinctly increased in patient 56 with the heterozygous variant c.1148C>T; p.Ala383Val in SPTLC2. According to the literature, levels were four-and tenfold elevated compared to healthy controls, respectively, whereas the physiological sphingoid bases C18-sphingosine and C18-sphinganine (b) were only slightly elevated within the normal range. These results confirm the pathogenicity of the shown variant in terms of gain-of-function mutation. et al. 2014) . In other publications focused on CMT, this distribution could consistently be confirmed with only few deviations discussing whether GJB1 or MPZ placed second in the gene ranking of demyelinating neuropathies. In genetically confirmed axonal CMT cases, either GJB1 or MFN2 were the most frequently identified underlying genes (Saporta et al. 2011; Murphy et al. 2012a; Gess et al. 2013; Sivera et al. 2013; Fridman et al. 2015; Rudnik-Sch€ oneborn et al. 2016) . SH3TC2, however, appears to be underestimated in the previous studies if compared to our results. With 9.9%, SH3TC2 places third in the overall ranking next to MPZ and therefore represents the most frequent AR gene in hereditary neuropathies identified in our cohort.
MPZ, and MFN2 (DiVincenzo
MFN2 was detected in our study in both AD and AR mode of inheritance. In spite being first and typically described in association with AD (or de novo) transmission (Z€ uchner et al. 2004) , affected families with an underlying AR inheritance have been previously described as well (Nicholson et al. 2008) . GJB1, one of the most abundant genes in the CMT context throughout the literature, follows XL inheritance, but typically affects female patients as well. In our study, 40% of the individuals with an underlying mutation in GJB1 were women. Xinactivation has been previously discussed as a relevant factor explaining the pronounced phenotypic variability in female patients (Murphy et al. 2012b) . As it seemed unchanged from healthy controls in blood, however, the authors discussed a preferential X-inactivation pattern in Schwann cells.
In all studies, the rate of genetically unsolved cases was markedly higher in axonal than in demyelinating CMT ranging from 38.7% (Sivera et al. 2013 ) to 86.9% (Rudnik-Sch€ oneborn et al. 2016 for the axonal cases and from 14.4% (Sivera et al. 2013 ) to 44.0% (RudnikSch€ oneborn et al. 2016 . In our cohort, regardless of electrophysiological patterns, 19.8% of all cases were genetically solved. Furthermore, in another 201 examined cases (32.8%), at least one variant was identified that could possibly contribute to or explain the patient's phenotype, but based on the current data situation cannot be classified as 'likely pathogenic' according to the American College of Genetics and Genomics criteria. In addition, the relatively low hit rate could be related to some differences from the previous studies, particularly a selection bias toward the more complex cases because of pre-testing of the most frequent genes prior to the panel diagnostic in some cases. Below, we further discuss the potential limitations but also the benefits comprised by these differences. Our study differs from the previous ones in two aspects:
First, not all patients included in our analysis come from the same diagnostic center. However, clinical information is an important scaffold to evaluate the pathogenicity of a variant 'Rare diseases' -the role of phenotype related multigene panels in genetic counseling Especially in rare diseases, broad molecular genetic analyses are of increasing importance. Defined by a prevalence below two of 2000 individuals, rare diseases are usually associated with diagnostic pitfalls such as unspecific symptoms, variable phenotypes, incomplete family history, and regionally centered clinicians' awareness and expertise (Valdez et al. 2016) . It is assumed that the preponderance of rare diseases is at least partially caused by an underlying genetic defect (Boycott et al. 2013) . However, traditional Sanger sequencing of one suspected underlying gene at a time requires detailed phenotypic considerations to eliminate the less and prioritize the most probable out of about 80 genes known to be potentially underlying. In early disease stages, when the classical phenotype is not fully developed yet, this is especially challenging. But also in advanced stages, when for example the electrophysiological distinction of demyelinating or axonal neuropathy becomes more and more blurred, the phenotypic depiction can be difficult and broader genetic examinations appear useful. As one notable example, we described patient 56, who finally received the diagnosis of HSAN 1 after more than 30 years of diagnostic struggling. Functional analysis of the sphingolipid profile revealed a measurable increase in neurotoxic 1-deoxy-sphingolipids in blood plasma and therefore coincided with the results of molecular genetic testing: the identification of the heterozygous variant c.1148C>T; p.Ala383Val in SPTLC2.
Gene panel analyses based on next generation sequencing enable a simultaneous screening of multiple genes including frequent and rare genes at once (i. a. Gl€ ockle et al. 2014). After computational analysis, a selection of variants is assessed and discussed concerning the type of mutation, its presumed effect on the related protein, inheritance, allele frequency in healthy control populations, and phenotypic correlations. It therefore remains important, to precisely examine and describe the individual patient's phenotype to facilitate the retrospective choice of the most relevant gene and mutation out of entire gene panel results (Rudnik-Sch€ oneborn et al. 2016) . As an illustrative example, we described patient 9 with the heterozygous variant c.785T>C; p.Leu262Pro in the KIF5A gene which has not previously been described in the literature. However, considering the clinical overlap between the CMT and hereditary spastic paraparesis/paraplegia phenotype in this patient facilitated the evaluation of pathogenicity as this phenomenon is typically associated to KIF5A mutations .
Detailed phenotype characterizations, which have traditionally been used to prospectively narrow the selection of genes to the best matching one, will therefore remain relevant.
Like multiple gene panel analysis, whole exome and genome sequencing are also multiple gene testing approaches providing an even broader spectrum of genetic data, which include screening of candidate genes which have not yet been described in association with the disease in question (Majewski et al. 2011; Singleton 2011) . This is especially relevant in cases showing an unspecific phenotype, for which a certain panel subtype cannot easily be chosen. Difficulties arising with the use of NGS data in genetic diagnostics are the (lack of) coverage of individual genes within whole exome analyses on the one, and the highly complex interpretation of the results on the other hand (Majewski et al. 2011; Singleton 2011) . While variants of uncertain significance, however, can be further evaluated by examining the patient's parents or siblings in a trio-exome, insufficient enrichment and coverage still remain unsolved. One example is case 72 showing two mutations in HK1, of which we consider an underlying pathogenicity conceivable with an AR inheritance. As shown in Fig. 2, HK1 is not enriched in the whole exome dataset because of its position outside the exon, but shows sufficient coverage in the optimized panel. While exome sequencing can generate a much larger choice of variants to assess and verify, it may also lead to false negative results, 'holes' in the whole exome, in which relevant mutations appear outside of the enriched genomic regions (Choi et al. 2009; Majewski et al. 2011; Singleton 2011) . The panel approach, on the other hand, allows the informed selection of relevant regions as well as strong optimization of coverage on relevant targets. Higher average coverages, infeasible for exome enrichment approaches and even more so for whole-genome sequencing, reduce the risk of false negative results because of sampling bias offering high diagnostic value at a much lower price tag.
Early diagnosis -the therapeutic impact
Of the available diagnostic methods in hereditary rare diseases, multiple gene panel based analyses using NGS are a time-and cost-effective method to significantly shorten the duration from onset to diagnosis and treatment if available. Familial amyloidotic polyneuropathy (FAP) is a progressive systemic disease first manifesting as an axonal, sensorimotor and autonomous polyneuropathy. Causative treatment options either prevent the amyloid formation by stabilization of the tetrameric quaternary structure (Coelho et al. 2012) or remove the main source of TTR by liver transplantation (Holmgren et al. 1993 ) -but are all approved for the first stage of FAP only, when patients still present ambulatory. Especially in patients with the late-onset phenotype clinically defined by an age older than 50 years at first manifestation, diagnostic pitfalls such as unspecific initial symptoms, lacking family history, and abundant comorbidities relevant for differential diagnosis make an early determination a clinicians' challenge (Dohrn et al. 2013) . Within the frame of this study, we identified three patients with pathogenic mutations in the TTR gene encoding for the homotetrameric transport protein of thyroxin and retinol. We thus conclude that even in a very early disease stage, when the typical phenotype of FAP has not been fully developed, a broad diagnostic panel can identify the underlying mutations and therefore enable an early causative treatment in an otherwise fatal systemic disease.
Discussing the therapeutic consequences of a genetically confirmed diagnosis, the exemplary case description of patient 29 illustrates that next generation-based panel diagnostics can be crucial to avoid unnecessary immunosuppressant treatment that is both toxic and expensive. The panel method precisely tracks variants in frequent genes including those that have previously been missed by Sanger sequencing. We were therefore able to solve the case, distinguishing the presumed diagnosis CMT from a differentially discussed chronic inflammatory demyelinating polyneuropathy to be the underlying cause in a demyelinating polyneuropathy.
Apart from direct therapeutic implications, a concise genetic diagnosis constitutes a principal requirement for participation in clinical trials. Examples can be both trials on targeted gene therapies as currently conducted in patients with TTR-related familial amyloidosis and observational studies focusing on the natural disease course.
Conclusion
Hereditary neuropathies comprise a geno-and phenotypically heterogeneous group of rare diseases subdivided by neurophysiology, mode of inheritance, and typically associated clinical patterns. As knowledge on causative genes and related phenotypes has been rising at a gallop, panel based next generation sequencing is a diagnostically highly sensitive, time-and cost-effective approach to assist clinicians identify the correct diagnosis and enable early causative treatment considerations. To facilitate the challenging interpretation of data considering their spreading availability, interdisciplinary collaborations between molecular geneticists, clinicians, and (neuro-)pathologists are of growing importance to increase significant results and solve rates. A precise phenotyping including the clinical, electrophysiological, and sometimes the pathological patterns of neuropathy therefore remains of utmost necessity.
